GlassScriptPhysician profile
Reed J Yaras
NPI 1922561877
$3,499.88
in general payments reported to CMS, 2019-2025
8 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 80% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $492 · 2024: $1,560 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,499.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,968.21 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $816.79 | 2023-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Globus Medical, INC. | $335.97 | 2025 | Senza |
| Tersera Therapeutics LLC | $124.29 | 2024 | Prialt |
| Abbvie INC. | $99.29 | 2025 | |
| Saluda Medical Americas, INC. | $66.00 | 2025 | Evoke |
| Curonix LLC | $50.74 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stryker Corporation | $38.59 | 2025 | Optablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Yaras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.